Vita Life Sciences Ltd (ASX: VLS) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Vita Life Sciences Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$149.26 million
P/E Ratio
13.95
Dividend Yield
5.25%
Shares Outstanding
54.08 million
Earnings per share
0.198
Dividend per share
0.15
Year To Date Return
12.60%
Earnings Yield
7.17%
Franking
N/A
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Vita Life Sciences Ltd (ASX: VLS)
Latest News
Dividend Investing
33 ASX shares going ex-dividend next week
VLS ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Vita Life Sciences Ltd
Vita Life Sciences Ltd. engages in the formulation, packaging, sale, and distribution of vitamins and supplements. It operates through the following geographical segments: Australia, Singapore, Malaysia, and Others. The Others segment consists of business operations in Thailand, Vietnam, Indonesia, and China. The company was founded in 1947 and is headquartered in Kirrawee, Australia.
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 01 Sep 2026 | Henry Townsing | Buy | 30,000 | $82,800 |
On-market trade.
|
| 09 Jun 2026 | Andrew O'Keefe | Issued | 600,000 | $1,515,000 |
Issue of securities.
|
| 05 Jun 2026 | Henry Townsing | Sell | 23,184 | $56,367 |
On-market trade.
|
| 29 May 2026 | Henry Townsing | Sell | 29,947 | $72,226 |
On-market trade.
|
| 07 May 2026 | Henry Townsing | Sell | 40,753 | $101,983 |
On-market trade.
|
| 30 Apr 2026 | Andrew O'Keefe | Sell | 272,483 | $690,008 |
As advised by the company. 272,483 shares were sold back to the Company under
the terms of the LTIP. 27,517 LTIP unquoted shares were converted into quoted shares. |
| 20 Apr 2026 | Peter Osborne | Buy | 2,000 | $5,000 |
On-market trade.
|
| 17 Dec 2025 | Henry Townsing | Buy | 130,000 | $318,500 |
Off-market trade.
|
| 07 Oct 2025 | Peter Osborne | Buy | 2,000 | $4,860 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Henry George Townsing | Non-Executive DirectorNon-Executive Chairman | Dec 2011 |
Mr Townsing has over 30 years of experience in corporate finance and private equity. He was a Director of the Company, from 1985 to 1992, 2004 to 2009 and was reappointed a director on 22 December 2011.
|
| Mr Andrew O'Keefe | Managing Director | Oct 2016 |
Mr O'Keefe has over 20 years of experience within the Australian pharmaceutical and healthcare industry. During his career Mr O'Keefe has held senior leadership positions in publicly listed companies. Andrew O'Keefe was appointed to the position of Chief Executive Officer - Herbs of Gold Australia in Oct 2014.
|
| Mr Jack Teoh | Non-Executive Director | Sep 2022 |
Mr Teoh is a businessman involved in a range of private companies, with particular experience in finance and technology. He was also a director of Tuas Limited from July 2020 till August 2022, and Total Forms Pty Ltd, a private Australian software business. Mr. Jack Teoh is also on the Board of TPG Telecom as a non-executive director since March 2021.
|
| Mr Peter Osborne | Non-Executive Director | Aug 2023 |
Mr Osborne has experience in business development, sales and marketing, trade development, export and investment facilitation and promotion. He served as Australian Senior Trade Commissioner in Beijing, Shanghai, Hong Kong and Taiwan over 20-years prior to becoming Managing Director Asia for Blackmores Ltd in 2009 - 2020. He is also a director of ATP Science; strategic advisor to Team Global Express, Edison Partners, advisor to Daiken Biomedical (Taiwan) and, external advisor to Bain & Company and Blackstone.
|
| Mr Chin Leng Khoo | Chief Financial OfficerCompany Secretary | Jun 2017 |
-
|
| Chin Leng Khoo | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Chemical Overseas Limited | 8,551,439 | 15.40% |
| Vicky Teoh | 8,435,693 | 15.20% |
| Barings Acceptance Limited | 7,371,832 | 13.30% |
| Anglo Australian Christian & Charitable Fund | 6,276,040 | 11.30% |
| Tie Lim Sung | 4,010,000 | 7.20% |
| HSBC Custody Nominees (Australia) Limited | 3,281,060 | 6.00% |
| South Seas Holdings Pty Limited | 1,345,430 | 2.50% |
| J P Morgan Nominees Australia Pty Limited | 956,902 | 1.80% |
| Andrew Warren O'Keefe | 890,000 | 1.60% |
| Redbrook Nominees Pty Ltd | 816,067 | 1.50% |
| Tan Teik Wei | 811,607 | 1.50% |
| B F A Pty Ltd | 637,591 | 1.20% |
| K S Beh | 524,890 | 0.90% |
| Citicorp Nominees Pty Limited | 329,168 | 0.60% |
| Crx Investments Pty Limited | 300,000 | 0.60% |
| Shaun Rutherford | 291,089 | 0.50% |
| Crx Securities Pty Limited | 270,000 | 0.50% |
| Finclear Services Pty Ltd | 259,299 | 0.50% |
| Kangiara Pty Limited | 252,268 | 0.50% |
| Chin L Khoo | 249,000 | 0.40% |
